Arcellx, Inc. (ACLX) is a biotechnology company focused on the development of novel cell-based immunotherapies. The company utilizes cutting-edge technology and innovative approaches to target and eliminate cancer cells. In order to assess the potential of ACLX stock, it is important to analyze various technical indicators and metrics.

The Relative Strength Index (RSI) is a widely used technical indicator that measures the strength and momentum of a stock's price movements. It provides information on whether a stock is overbought or oversold. The ACLX stock RSI can help investors determine if the stock is currently trading at a price that is too high or too low relative to its historical performance.

Arcellx (ACLX) Technical Analysis

Stay informed about Arcellx, Inc. (ACLX) with technical analysis indicators including RSI, ADX, MACD, ROC, STOCHRSI, and WILLR. Analyze stock trends and make informed trading decisions. Get the latest insights on ACLX's stock performance.

Arcellx, Inc. (ACLX) Technical Analysis Indicators

Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and product candidates for solid tumor programs. It has strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize CART-ddBCMA. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.

Arcellx

NASDAQ

This suggests that the technical indicators do not strongly favor either a buying or selling stance. In such cases, investors may need to rely on additional fundamental or market analysis to make a well-informed decision.

Balanced or Uncertain

MACD

WILLR

STOCHRSI

Free

is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

Name	Value	Action	infoPnL (10y)
auto_graphRSI	68.90	Neutral	19.7%
auto_graphMACD	33.21	Neutral	955.9%
auto_graphCCI	181.61	Sell	261.4%
auto_graphADX	31.96	Neutral	-
auto_graphATR	65.18	Buy	-
auto_graphWILLR	-21.43	Neutral	331.4%
auto_graphROC	132.99	Neutral	609.7%
auto_graphSTOCHRSI	92.29	Sell	103.7%

Buy	1	-87.50%
Hold	5	-37.50%
Sell	2	-75.00%

Trendlines, Support and Resistance

Welcome to Stocklytics

Technical Indicators

Indicator Ratings

Balanced or Uncertain

Arcellx (ACLX) Technical Analysis

Keep an eye on Arcellx

Frequently Asked Questions

What are the technical signals for Arcellx (ACLX) stock based on the last 30 days?

Take Your Investments to a Whole New Level